美国血液学会/国际血栓与止血学会2024年儿童静脉血栓栓塞治疗指南更新
美国血液学会(ASH)与国际血栓与止血学会(ISTH)基于GRADE方法更新2018年儿童静脉血栓栓塞(VTE)治疗指南,形成20条推荐并提供抗凝药使用实施指导,重点涉及直接口服抗凝药(DOACs)在儿童各类VTE治疗中的作用,结论指出需进一步研究。
要点
- ASH/ISTH联合更新儿童VTE治疗指南,共形成20条推荐。
- 指南重点推荐涉及DOACs在儿童各类VTE治疗中的作用。
- 指南同时提供儿童患者抗凝药最佳使用的实施指导。
核心结论
- 指南就儿童VTE治疗达成20条推荐,并提供抗凝药最佳使用的实施指导。
- 关键推荐包括DOACs在儿童各类VTE治疗中的作用。
- 结论指出需进一步研究,重点为理解临床未怀疑血栓在不同患者亚群中的自然病史及获取DOACs在儿童中使用的真实世界数据。
研究设计与样本
- ASH/ISTH组建多学科指南小组以减少利益冲突潜在偏倚,但未确定无利益冲突的患者代表。
- 堪萨斯大学健康系统支持指南制定过程,更新或执行截至2024年的系统证据评价。
- 小组聚焦2018年问题中 interim 数据最多的部分,采用GRADE方法(包括证据到决策框架)评估证据并形成推荐,推荐经过公开评论。
主要发现
- 过去6年中参与VTE治疗试验的儿童数量增加10倍。
- 小组就20条推荐达成一致。
- 关键推荐涉及DOACs在儿童各类VTE治疗中的作用。
关键数值与推荐
- 指南共形成20条推荐。
- 推荐涉及DOACs在儿童各类VTE治疗中的作用。
- 提供儿童患者抗凝药最佳使用的实施指导。
临床怎么用
- 指南旨在支持患者、临床医生和其他医疗专业人员管理儿童VTE。
- 原文未据此给出具体推荐。
局限性
- 未确定无利益冲突的患者代表。
- 需进一步研究,重点为理解临床未怀疑血栓在不同患者亚群中的自然病史及获取DOACs在儿童中使用的真实世界数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The American Society of Hematology (ASH) guidelines on treatment of pediatric venous thromboembolism (VTE) were published in 2018. In the last 6 years, there has been a 10-fold increase in the number of children involved in VTE treatment trials. OBJECTIVE: The ASH Committee on Quality and Guidelines agreed to update the pediatric guidelines in conjunction with the International Society on Thrombosis and Haemostasis (ISTH). These ASH/ISTH evidence-based guidelines are intended to support patients, clinicians, and other health care professionals in the management of pediatric patients with VTE. METHODS: ASH/ISTH formed a multidisciplinary guideline panel to minimize potential bias from conflicts of interest. An unconflicted patient representative was not identified. The University of Kansas Health System supported the guideline development process, updating or performing systematic evidence reviews up to 2024. The panel focused specifically on the 2018 questions for which there was the greatest amount of interim data. The panel used the GRADE (Grades of Recommendation, Assessment, Development, and Evaluation) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subject to public comment. RESULTS: The panel agreed on 20 recommendations and also provided implementation guidance on the optimal use of anticoagulants in pediatric patients. Key recommendations of these guidelines include the role of DOACs in the treatment of a variety of pediatric VTEs. CONCLUSIONS: Further research is required. Key priorities are understanding the natural history of clinically unsuspected thrombosis across a range of patient subpopulations and obtaining real-world data on the use of DOACs in children.
引用
- Monagle P, Azzam M, Bercovitz R, et al. American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients. Blood Adv. 2025. PMID: 40423983. doi:10.1182/bloodadvances.2024015328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。